Alnylam Pharmaceuticals 2026: Revenue $1.46B, EPS $15.72— 10-Q Summary
Alnylam Pharmaceuticals reported 2026 revenue of $1.46B, up 16.7% YoY, and net income of $2.17B, up 640.5% YoY. Diluted EPS was $15.72, up 634.6%. Nine-month revenue rose 50% to $3.92B, with AMVUTTRA sales growing 65%. The company expanded clinical trials for several drugs and expects increased R&D and commercial investment.
How this was made
The 30-second read
Why it matters
For traders, the key decision inputs are the reported revenue/EPS figures and the incremental clinical-trial actions (ATTR-CM Phase 3 expansion, mivelsiran CAA enrollment completion, new Down syndrome-associated Alzheimer’s trial start, and ongoing zilebesiran cardiovascular outcomes Phase 3). These can affect near-term estimate revisions and risk perception around launch scaling and trial timelines.
Market read
A company-specific 10-Q datapoint with both financial results and late-stage trial scaling details, relevant for updating short- to medium-term biotech expectations.
What to watch
The summary notes collaboration revenue fell sharply due to non-recurrence of a Roche milestone; traders may focus on whether product growth fully offsets collaboration volatility and how much future investment is required for scaled launches.
Background
The piece summarizes Alnylam’s SEC Form 10-Q (Oct. 29, 2026), including financial highlights and updates across its RNAi product portfolio and late-stage clinical programs.
Ticker impact
Alnylam’s 10-Q summary reports 2026-period revenue of $1.46B and diluted EPS of $15.72, plus major program updates (AMVUTTRA, GIVLAARI/OXLUMO/ONPATTRO, and ATTR-CM trial expansion).
Likely upward bias as investors price stronger reported revenue/EPS and continued ATTR-CM and cardiovascular outcomes trial progress.
The article is a first-report style 10-Q summary with multiple new figures (revenue, net income, EPS) and incremental trial actions (Phase 3 expansion, enrollment completion, new trial start), which are typically supportive for biotech sentiment and estimates.
Market effects
Biotech investors may recalibrate read-through on RNAi/ATTR-CM franchise momentum and the probability-weighting of late-stage cardiovascular outcomes programs.
Primarily US-listed biotech sentiment; limited direct regional spillover implied by the filing summary.
ATTR-CM and cardiovascular outcomes trial progress can influence global RNAi/rare-disease competitive positioning, but the article is US-focused on reported results.
Counterpoint
Large EPS growth may be influenced by accounting/one-time effects not visible in the summary, so price reaction could be muted if cash flow or guidance details are weaker in the full filing.
Key entities
- companyAlnylam Pharmaceuticals, Inc.
Subject of the 10-Q summary, reporting higher revenue and EPS and providing updates across AMVUTTRA, GIVLAARI, OXLUMO, ONPATTRO, and multiple Phase 3/clinical programs.
- partnerRoche
Collaboration revenue declined because a Roche milestone recorded a year earlier did not recur, per the summary.
